PMID- 32266127
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - The Predictive Value of Estrogen Receptor 1 on Adjuvant Chemotherapy in Locally 
      Advanced Colorectal Cancer: A Retrospective Analysis With Independent Validation 
      and Its Potential Mechanism.
PG  - 214
LID - 10.3389/fonc.2020.00214 [doi]
LID - 214
AB  - Purpose: To investigate the predictive biomarker value of estrogen receptor 1 
      (ESR1) expression in tumor tissue on adjuvant chemotherapy in curatively resected 
      colorectal cancer (CRC). Methods: A total of 467 CRC patients in 2007-2010 were 
      retrospectively evaluated. Clinical information and follow-up data were retrieved 
      from hospital registries and patient files. What's more, we used an external 
      independent cohort (n = 511) from GSE39582 for further validation. Overall 
      survival was estimated by the Kaplan-Meier method, and the survival curves were 
      compared by log-rank tests. Cox proportional hazards models were used for 
      multivariate analyses to calculate the hazard ratios (HRs) and test independent 
      significance. Immunohistochemistry and Western blot were applied to detect 
      protein expression of ESR1 in CRC patients and cell lines. The stable knockdown 
      and overexpressed cells were transduced with the lentivirus. Cell viability was 
      measured by an MTS reagent. Results: The predictive value of ESR1 was 
      investigated in locally advanced CRC patients. Kaplan-Meier analysis indicated 
      that ESR1 expression was significantly correlated with OS in patients receiving 
      adjuvant chemotherapy from these cohorts, with p = 0.015 and p < 0.001, 
      respectively. ESR1 expression was significantly correlated with 5-flurouracil 
      (5-FU)-based adjuvant chemotherapy in training with an HR of 1.792 (95%CI: 
      1.100-2.921, p = 0.019). Downregulation of ESR1 was related with enhanced 
      chemosensitivity to 5-FU in CRC cell lines, while upregulation of ESR1 was 
      correlated with decreased chemosensitivity. Conclusions: The present study 
      manifest clinical validity of ESR1 expression as a predictive biomarker on 
      5-FU-based adjuvant chemotherapy in stage II-III CRC.
CI  - Copyright (c) 2020 Ye, Cheng, Deng, Deng, Li, Zhang and Lan.
FAU - Ye, Shu-Biao
AU  - Ye SB
AD  - Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, 
      Department of Colorectal Surgery, Guangdong Institute of Gastroenterology, The 
      Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Cheng, Yi-Kan
AU  - Cheng YK
AD  - Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, 
      Department of Radiation Oncology, Guangdong Institute of Gastroenterology, 
      Guangzhou, China.
FAU - Deng, Ru
AU  - Deng R
AD  - Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, 
      Department of Oncology, Guangdong Institute of Gastroenterology, The Sixth 
      Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Deng, Yanhong
AU  - Deng Y
AD  - Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, 
      Department of Oncology, Guangdong Institute of Gastroenterology, The Sixth 
      Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Li, Peisi
AU  - Li P
AD  - School of Medicine, Sun Yat-sen University, Guangzhou, China.
FAU - Zhang, Lin
AU  - Zhang L
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Department of Clinical Laboratory, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
FAU - Lan, Ping
AU  - Lan P
AD  - Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, 
      Department of Colorectal Surgery, Guangdong Institute of Gastroenterology, The 
      Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200320
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7100261
OTO - NOTNLM
OT  - ESR1
OT  - adjuvant chemotherapy
OT  - colorectal cancer
OT  - predictive
OT  - retrospective analysis
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
PMCR- 2020/01/01
CRDT- 2020/04/09 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/02/07 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.00214 [doi]
PST - epublish
SO  - Front Oncol. 2020 Mar 20;10:214. doi: 10.3389/fonc.2020.00214. eCollection 2020.